Atea Pharmaceuticals, Inc.
AVIRNasdaqCIK 1593899HealthcareFiscal year ends Dec 31
Reports and events: 83 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1220:45 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-347021 |
| 2026-08-1220:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346888 |
| 2026-06-2220:53 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-277639 |
| 2026-05-1220:45 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219678 |
| 2026-05-1220:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219507 |
| 2026-04-2720:45 ET | DEF 14A | Proxy statementPeriod 2026-06-18 | 0001193125-26-182293 |
| 2026-03-0521:50 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-094159 |
| 2026-03-0521:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093961 |
| 2026-01-0814:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-007081 |
| 2025-11-1221:45 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-277815 |
| 2025-11-1221:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277627 |
| 2025-08-0720:35 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-105123 |
| 2025-08-0720:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-175433 |
| 2025-06-2021:16 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-143750 |
| 2025-05-1220:45 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069367 |
| 2025-05-1220:23 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-117809 |
| 2025-04-2921:00 ET | DEF 14A | Proxy statementPeriod 2025-06-20 | 0001193125-25-104019 |
| 2025-04-1716:23 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000921895-25-001112 |
| 2025-04-1712:06 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-083523 |
| 2025-04-0113:19 ET | 8-K | 8.01 Other events | 0001193125-25-069932 |
| 2025-03-2410:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-060794 |
| 2025-03-2115:58 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000921895-25-000843 |
| 2025-03-0621:45 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-034808 |
| 2025-03-0621:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-048426 |
| 2025-03-0414:27 ET | SCHEDULE 13D | Ownership report, active investor | 0000921895-25-000684 |
| 2025-02-2413:17 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-032826 |
| 2025-01-1423:54 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-005424 |
| 2024-12-1614:50 ET | SCHEDULE 13D | Ownership report, active investor | 0001373604-24-000114 |
| 2024-11-0721:41 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123447 |
| 2024-11-0721:27 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-253143 |
| 2024-08-0720:45 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-092914 |
| 2024-08-0720:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-195895 |
| 2024-06-2121:21 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-165886 |
| 2024-05-1420:43 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059699 |
| 2024-05-1420:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-138249 |
| 2024-04-2620:21 ET | DEF 14A | Proxy statementPeriod 2024-06-21 | 0000950170-24-049178 |
| 2024-02-2822:00 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-022226 |
| 2024-02-2821:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-050724 |
| 2023-11-2811:00 ET | SC 13D/A | Ownership report, active investor, amended | 0001214659-23-015585 |
| 2023-11-0821:43 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-061213 |
| 2023-11-0821:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-273532 |
| 2023-08-0820:46 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-039920 |
| 2023-08-0820:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-206247 |
| 2023-06-2121:02 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-23-171257 |
| 2023-05-2213:00 ET | SC 13D | Ownership report, active investor | 0001214659-23-007616 |
| 2023-05-0820:41 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-018869 |
| 2023-05-0820:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-138257 |
| 2023-04-2820:07 ET | DEF 14A | Proxy statement | 0000950170-23-015773 |
| 2023-02-2821:56 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-005186 |
| 2023-02-2821:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-053843 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.